Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery - PubMed (original) (raw)
Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery
Bruno Coutard et al. Antiviral Res. 2014 Jun.
Abstract
Seasonal and pandemic flaviviruses continue to be leading global health concerns. With the view to help drug discovery against Dengue virus (DENV), a fragment-based experimental approach was applied to identify small molecule ligands targeting two main components of the flavivirus replication complex: the NS3 helicase (Hel) and the NS5 mRNA methyltransferase (MTase) domains. A library of 500 drug-like fragments was first screened by thermal-shift assay (TSA) leading to the identification of 36 and 32 fragment hits binding Hel and MTase from DENV, respectively. In a second stage, we set up a fragment-based X-ray crystallographic screening (FBS-X) in order to provide both validated fragment hits and structural binding information. No fragment hit was confirmed for DENV Hel. In contrast, a total of seven fragments were identified as DENV MTase binders and structures of MTase-fragment hit complexes were solved at resolution at least 2.0Å or better. All fragment hits identified contain either a five- or six-membered aromatic ring or both, and three novel binding sites were located on the MTase. To further characterize the fragment hits identified by TSA and FBS-X, we performed enzymatic assays to assess their inhibition effect on the N7- and 2'-O-MTase enzymatic activities: five of these fragment hits inhibit at least one of the two activities with IC50 ranging from 180μM to 9mM. This work validates the FBS-X strategy for identifying new anti-flaviviral hits targeting MTase, while Hel might not be an amenable target for fragment-based drug discovery (FBDD). This approach proved to be a fast and efficient screening method for FBDD target validation and discovery of starting hits for the development of higher affinity molecules that bind to novel allosteric sites.
Keywords: Antiviral screening; Dengue virus; Fragment-based drug discovery; NS3 helicase; NS5 methyltransferase.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
- Development of specific dengue virus 2'-O- and N7-methyltransferase assays for antiviral drug screening.
Barral K, Sallamand C, Petzold C, Coutard B, Collet A, Thillier Y, Zimmermann J, Vasseur JJ, Canard B, Rohayem J, Debart F, Decroly E. Barral K, et al. Antiviral Res. 2013 Sep;99(3):292-300. doi: 10.1016/j.antiviral.2013.06.001. Epub 2013 Jun 12. Antiviral Res. 2013. PMID: 23769894 - Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design.
Benmansour F, Trist I, Coutard B, Decroly E, Querat G, Brancale A, Barral K. Benmansour F, et al. Eur J Med Chem. 2017 Jan 5;125:865-880. doi: 10.1016/j.ejmech.2016.10.007. Epub 2016 Oct 5. Eur J Med Chem. 2017. PMID: 27750202 - Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors.
Hernandez J, Hoffer L, Coutard B, Querat G, Roche P, Morelli X, Decroly E, Barral K. Hernandez J, et al. Eur J Med Chem. 2019 Jan 1;161:323-333. doi: 10.1016/j.ejmech.2018.09.056. Epub 2018 Oct 23. Eur J Med Chem. 2019. PMID: 30368131 - The dengue virus NS5 protein as a target for drug discovery.
Lim SP, Noble CG, Shi PY. Lim SP, et al. Antiviral Res. 2015 Jul;119:57-67. doi: 10.1016/j.antiviral.2015.04.010. Epub 2015 Apr 24. Antiviral Res. 2015. PMID: 25912817 Review. - Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, Vasudevan SG. Lescar J, et al. Antiviral Res. 2008 Nov;80(2):94-101. doi: 10.1016/j.antiviral.2008.07.001. Epub 2008 Jul 30. Antiviral Res. 2008. PMID: 18674567 Review.
Cited by
- High-throughput crystallographic fragment screening of Zika virus NS3 Helicase.
Godoy AS, Mesquita NCMR, Noske GD, Gawriljuk VO, Lithgo RM, Balcomb BH, Aschenbrenner JC, Tomlinson CWE, Winokan M, Scheen J, Marples PG, Chandran AV, Ni X, Thompson W, Fairhead M, Fearon D, Koekemoer L, Xavier ME, Walsh M, Oliva G, von Delft F. Godoy AS, et al. bioRxiv [Preprint]. 2024 Apr 29:2024.04.27.591279. doi: 10.1101/2024.04.27.591279. bioRxiv. 2024. PMID: 38746241 Free PMC article. Preprint. - Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor.
Jiang Y, Wu Y, Wang J, Ma Y, Yu H, Wang Z. Jiang Y, et al. Curr Med Chem. 2024;31(38):6204-6226. doi: 10.2174/0109298673294251240229070740. Curr Med Chem. 2024. PMID: 38529602 Review. - Development of Allosteric NIK Ligands from Fragment-Based NMR Screening.
Anderson JJ, Grillo MJ, Harki DA. Anderson JJ, et al. ACS Med Chem Lett. 2023 Nov 3;14(12):1815-1820. doi: 10.1021/acsmedchemlett.3c00429. eCollection 2023 Dec 14. ACS Med Chem Lett. 2023. PMID: 38116406 - FGDB: a comprehensive graph database of ligand fragments from the Protein Data Bank.
Toti D, Macari G, Barbierato E, Polticelli F. Toti D, et al. Database (Oxford). 2022 Jun 27;2022:baac044. doi: 10.1093/database/baac044. Database (Oxford). 2022. PMID: 35763362 Free PMC article. - Chemical biology and medicinal chemistry of RNA methyltransferases.
Fischer TR, Meidner L, Schwickert M, Weber M, Zimmermann RA, Kersten C, Schirmeister T, Helm M. Fischer TR, et al. Nucleic Acids Res. 2022 May 6;50(8):4216-4245. doi: 10.1093/nar/gkac224. Nucleic Acids Res. 2022. PMID: 35412633 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials